Literature DB >> 17562851

Dihydrocucurbitacin B inhibits delayed type hypersensitivity reactions by suppressing lymphocyte proliferation.

José M Escandell1, M Carmen Recio, Salvador Máñez, Rosa M Giner, Miguel Cerdá-Nicolás, Rosario Gil-Benso, José-Luis Ríos.   

Abstract

We have studied the effects of dihydrocucurbitacin B, a triterpene isolated from Cayaponia tayuya roots, on different models of delayed type hypersensitivity (DTH) in mice, as well as on T-lymphocyte proliferation and the mediators involved. In experiments with mice, dihydrocucurbitacin B inhibited the inflammatory reactions induced by oxazolone, dinitrofluorobenzene, and sheep red blood cells, reducing both the edema and cell infiltration. Moreover, the analysis of inflamed tissues showed that dihydrocucurbitacin B reduced the presence of the most relevant cytokines implicated in these processes, including interleukin-1 beta, interleukin-4, and tumor necrosis factor-alpha. Dihydrocucurbitacin B was also found to inhibit the proliferation of phytohemagglutinin-stimulated human T lymphocytes (IC(50) = 1.48 microM), halting the cell cycle in the G(0) phase. In addition, the triterpene reduced the production of interleukin-2, interleukin-4, interleukin-10, and interferon-gamma in human T lymphocytes, and it hampered the induction of the principal cyclins involved in the cell cycle, including A(1), B(1), D(2), and E(1). Finally, dihydrocucurbitacin B was found to exert a selective inhibition on the nuclear factor of activated T cells (NFAT) in human lymphocytes without affecting the calcium influx. Taken together, these results suggest that dihydrocucurbitacin B curbs DTH reactions by inhibiting NFAT, which in turn suppresses the proliferation of the most relevant cells involved in DTH reactions, namely the T cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17562851     DOI: 10.1124/jpet.107.122671

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Bcl-2 is a negative regulator of interleukin-1beta secretion in murine macrophages in pharmacological-induced apoptosis.

Authors:  J M Escandell; M C Recio; R M Giner; S Máñez; J L Ríos
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Activated kRas protects colon cancer cells from cucurbitacin-induced apoptosis: the role of p53 and p21.

Authors:  José M Escandell; Pawan Kaler; M Carmen Recio; Takehiko Sasazuki; Senji Shirasawa; Leonard Augenlicht; José-Luis Ríos; Lidija Klampfer
Journal:  Biochem Pharmacol       Date:  2008-05-08       Impact factor: 5.858

3.  Cucurbitacins - a promising target for cancer therapy.

Authors:  Abdullah A Alghasham
Journal:  Int J Health Sci (Qassim)       Date:  2013-01

Review 4.  Cucurbitacins - An insight into medicinal leads from nature.

Authors:  Ujjwal Kaushik; Vidhu Aeri; Showkat R Mir
Journal:  Pharmacogn Rev       Date:  2015 Jan-Jun

5.  Brazilian green propolis improves immune function in aged mice.

Authors:  Weina Gao; Jianquan Wu; Jingyu Wei; Lingling Pu; Changjiang Guo; Jijun Yang; Ming Yang; Haiji Luo
Journal:  J Clin Biochem Nutr       Date:  2014-07-01       Impact factor: 3.114

6.  Mutation of cysteine 46 in IKK-beta increases inflammatory responses.

Authors:  Ting Li; Vincent Kam Wai Wong; Zhi Hong Jiang; Shui Ping Jiang; Yan Liu; Ting Yu Wang; Xiao Jun Yao; Xiao Hui Su; Feng Gen Yan; Juan Liu; Elaine Lai-Han Leung; Xiao Qin Yi; Yuen Fan Wong; Hua Zhou; Liang Liu
Journal:  Oncotarget       Date:  2015-10-13

7.  Cucurbitacin E inhibits cellular proliferation and enhances the chemo-response in gastric cancer by suppressing AKt activation.

Authors:  Wenzhang Si; Jia Lyu; Zhengchuang Liu; Chunyang Wang; Jingjing Huang; Liping Jiang; Tonghui Ma
Journal:  J Cancer       Date:  2019-10-06       Impact factor: 4.207

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.